[EN] PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS<br/>[FR] COMPOSES DE PYRAZOLO(1,5A)PYRIMIDINE SERVANT D'AGENTS ANTIVIRAUX
申请人:NEOGENESIS PHARMACEUTICALS INC
公开号:WO2003101993A1
公开(公告)日:2003-12-11
The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.
Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase
作者:Janeta Popovici-Muller、Gerald W. Shipps、Kristin E. Rosner、Yongqi Deng、Tong Wang、Patrick J. Curran、Meredith A. Brown、M. Arshad Siddiqui、Alan B. Cooper、José Duca、Michael Cable、Viyyoor Girijavallabhan
DOI:10.1016/j.bmcl.2009.09.087
日期:2009.11
The present paper describes a novel series of HCV RNA polymerase inhibitors based on a pyrazolo[1,5-a]pyrimidine scaffold bearing hydrophobic groups and an acidic functionality. Several compounds were optimized to low nanomolar potencies in a biochemical RdRp assay. SAR trends clearly reveal a stringent preference for a cyclohexyl group as one of the hydrophobes, and improved activities for carboxylic acid derivatives. (C) 2009 Elsevier Ltd. All rights reserved.